ORIGINAL ARTICLE

Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation

C Demircan, H I Cikrikler, Z Engindeniz, H Cebicci, N Atar, V Guler, E O Unlu, B Ozdemir

Emerg Med J 2005;22:411–414. doi: 10.1136/emj.2003.012047

See end of article for authors' affiliations

Correspondence to:
Dr C Demircan, Uludag
Universitesi Tıp Fakültesi, İç
Hastalıkları Anabilim Dalı,
Bursa—Turkey;
demircan@uludag.edu.tr

Accepted for publication
26 April 2004

Objective: To compare the effectiveness of intravenous (IV) diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation (AF).

Methods: This prospective, randomised study was conducted in the Emergency Department of the Uludag University Medical Faculty Hospital, Bursa, Turkey. Forty AF patients with a ventricular rate ≥ 120 /minute and systolic blood pressure ≥ 95 mm Hg were included and randomised to receive IV diltiazem 0.25 mg/kg (maximum 25 mg) or metoprolol 0.15 mg/kg (maximum 10 mg) over 2 minutes. Blood pressures and heart rate were measured at 2, 5, 10, 15, and 20 minutes. Successful treatment was defined as fall in ventricular rate to below 100/minute or decrease in ventricular rate by 20% or return to sinus rhythm.

Results: Between January 2000 and July 2002, 40 patients (18 men, 22 women) met the inclusion criteria. Of these 20 (8 men, 12 women; mean age 60.2 years, range 31–82) received diltiazem and 20 (10 men, 10 women; mean age 64.0 years, range 31–82) received metoprolol. The success rate at 20 minutes for diltiazem and metoprolol was 90% ($n = 18$) and 80% ($n = 16$), respectively. The success rate at 2 minutes was higher in the diltiazem group. The percentage decrease in ventricular rate was higher in the diltiazem group at each time interval. None of the patients had hypotension.

Conclusion: Both diltiazem and metoprolol were safe and effective for the management of rapid ventricular rate in AF. However, the rate control effect began earlier and the percentage decrease in ventricular rate was higher with diltiazem than with metoprolol.

Atrial fibrillation (AF) is the commonest chronic arrhythmia, and its prevalence increases with age.^{1,2} AF is a potential risk factor for stroke by predisposing to thrombus formation, it may exacerbate heart failure due to loss of effective atrial contraction in compensated patients, and it may cause tachycardia induced cardiomyopathy when ventricular rate is not controlled.^{2–4} The goals of treatment for AF are to maintain effective cardiac output either by conversion to sinus rhythm when appropriate or by controlling ventricular rate and preventing embolic complications.^{5,6} Recent trials (the rate control versus electrical cardioversion for persistent atrial fibrillation (RACE) study and the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study) have demonstrated that therapies directed towards maintenance of sinus rhythm have no survival advantage over ventricular rate controlling strategies and that there is a lower risk of adverse drug effects with the rate control strategy.^{7,8}

The rapid ventricular rate increases the oxygen demand of the myocardium and may cause myocardial ischaemia and heart failure in the patients who have limited myocardial reserve. Symptoms including palpitation, angina, dyspnoea, and anxiety may be seen in patients with AF. To prevent complications and relieve the symptoms ventricular rate should be controlled in AF patients with a rapid ventricular rate.

Digitalis, β blockers and calcium channel blockers (verapamil and diltiazem) are all used in the treatment of rapid ventricular rate in AF.^{5,6,9–11} However, there has been no study comparing the effectiveness of these agents. Therefore, we conducted the present study to compare the effectiveness of intravenous (IV) diltiazem and metoprolol (the only parenteral β blocker preparation available in Turkey) in the management of rapid ventricular rate in AF in an emergency department (ED) setting.

METHODS

This prospective, double blind, randomised study was planned and conducted in the ED of the Uludag University Medical Faculty Hospital, Bursa, Turkey. The mean number of annual admissions to the ED is 24 000. We enrolled patients >18 years of age who had AF with a ventricular rate ≥ 120 /minute and systolic blood pressure ≥ 95 mm Hg. Patients were excluded if they had history of allergic reactions to diltiazem and metoprolol, congestive heart failure (New York Heart Association Class IV), systolic blood pressure <95 mm Hg, sick sinus syndrome, atrioventricular (AV) block (2nd or 3rd degree), pre-excitation syndromes, ventricular rate >220 /min, QRS >0.08 s, unstable angina pectoris, acute myocardial infarction, hyperthyroidism, temperature >38.0 °C, haemoglobin <11.0 g/dl, bronchial asthma, chronic obstructive pulmonary disease, diabetes mellitus, peripheral vascular disease, pregnancy, history of use of diltiazem, verapamil, digoxin, β blockers, theophylline, or β mimetics within the last five days (these drugs are cleared from the body within this time).^{12–14} All the enrolled patients received information about the study and gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki.

All patients had a 12-lead electrocardiogram at the beginning of the trial. We recorded and monitored their heart rate and blood pressures. The patients were randomly assigned to IV diltiazem 0.25 mg/kg (maximum 25 mg) or metoprolol 0.15 mg/kg (maximum 10 mg), which was administered by the nursing staff in the ED.^{12–15} For randomisation, we used cards with “metoprolol” or “diltiazem” put in sealed, opaque envelopes. The envelopes were

Abbreviations: AF, atrial fibrillation; ED, emergency department; IV, intravenous

Figure 1 Flow chart of the numbers of patients at different time points in the study.

shuffled to achieve randomisation. When an eligible patient was to be given treatment the top most envelope was opened by a nurse who was not taking part in the study. Then the drug was prepared by the nurse and the amount of the injection equalised with normal saline. The drug was administered to the patient in the presence of an observer (one of the authors) who was blinded to the contents of the injection. The patient's heart rate (with a rhythm strip at least 30 s long) and blood pressures were measured and recorded by a blinded observer at 2, 5, 10, 15, and 20 minutes to evaluate the effect of the treatment.

We defined successful treatment as achievement of a ventricular rate <100/min or a decrease in ventricular rate by 20% (<120/min at least) or conversion to sinus rhythm.¹³ Hypotension (systolic blood pressure <90 mm Hg) was accepted as a complication of treatment.^{13, 14} If the initial therapy was unsuccessful, an additional dose of IV diltiazem (0.35 mg/kg in diltiazem group and 0.25 mg/kg in the metoprolol group) was given as rescue treatment at the end of the study period. At this time point the observer was not blinded.

We analysed the data with SPSS for Windows (version 10.0). We used the *t* test for statistical comparisons of the differences between the two groups with regard to mean age, sex, pretreatment ventricular rate, systolic and diastolic blood pressures, treatment success ratios, and percentage decrease in ventricular rate. The paired *t* test was used for comparing within group changes at different time point. Differences in categorical variables were analysed with χ^2 square test.

RESULTS

Between January 2000 and July 2002, of 85 patients who were initially evaluated, 40 (18 men, 22 women; mean (SD) age 62.1 (12.9) years) met all the inclusion criteria and were enrolled in the study (fig 1). Twenty patients were randomised to receive diltiazem (8 men, 12 women; mean age 60.2 years, range 31–82) and 20 to receive metoprolol (10 men, 10 women; mean age 64.0 years, range 31–82). There was no significant difference between the groups as regards age and sex.

Table 1 Ventricular rate at the different time points of the study for each patient in both treatment groups

Treatment group and patient no.	Age	Sex	Minutes after administration of treatment						Result
			0	2	5	10	15	20	
Diltiazem									
1	65	F	145	112	105	102	102	100	Successful
2	72	F	150	96	75	68	72	76	Successful
3	70	M	140	94	103	90	85	80	Successful
4	41	M	178	101	94	93	95	99	Successful
5	50	M	150	85	90	92	98	96	Successful
6	64	M	146	105	108	108	108	98	Successful
7	70	F	192	132	120	118	117	118	Successful
8	56	F	174	170	132	136	138	124	Unsuccessful
9	69	M	128	107	103	100	96	98	Successful
10	67	F	124	68	74	72	80	72	Successful
11	73	F	146	112	94	98	100	98	Successful
12	63	F	160	132	104	108	106	98	Successful
13	60	M	160	43	139	108	105	98	Successful
14	47	F	170	154	142	124	116	112	Successful
15	31	M	158	145	124	120	95	96	Successful
16	66	F	162	122	120	118	116	115	Successful
17	50	F	186	130	126	130	140	130	Unsuccessful
18	82	F	169	121	108	104	104	99	Successful
19	68	M	140	98	96	93	95	103	Successful
20	40	F	150	105	108	92	80	90	Successful
Mean			156.4	116.6	108.2	103.7	102.4	100	
Metoprolol									
1	62	M	166	148	144	135	138	142	Unsuccessful
2	66	F	161	121	120	118	116	112	Successful
3	64	M	132	108	110	102	104	93	Successful
4	82	M	124	120	106	98	94	98	Successful
5	65	F	150	92	102	112	104	98	Successful
6	64	F	124	100	90	96	90	96	Successful
7	74	F	156	140	132	130	129	115	Successful
8	76	F	138	118	108	106	110	107	Successful
9	40	F	130	128	128	126	128	122	Unsuccessful
10	69	M	141	116	98	104	104	98	Successful
11	31	F	170	120	122	122	116	118	Successful
12	52	M	150	150	150	130	130	128	Unsuccessful
13	73	M	140	126	114	104	108	98	Successful
14	70	M	160	128	114	112	110	98	Successful
15	56	M	168	97	92	88	89	90	Successful
16	60	M	142	122	119	65	65	68	Successful
17	80	F	150	108	94	106	94	90	Successful
18	70	F	160	141	144	132	126	114	Successful
19	75	M	198	183	190	185	163	150	Unsuccessful
20	52	F	180	130	140	130	128	115	Successful
Mean			152	124.8	120.8	115	112.3	107.5	

Table 1 gives the changes in ventricular rate following treatment for all patients in both study groups. The changes in mean ventricular rate are shown in fig 2 and the percentage decrease in ventricular rate in relation to time in table 2. The rate of success of the treatments at 2, 5, 10, 15, and 20 minutes are given in table 3 and table 4 shows the changes in blood pressure with time in both the study groups. There were no significant differences between the mean

Figure 2 Mean ventricular rate in relation to time after treatment in the two treatment groups.

Table 2 Mean (SD) percentage decrease in ventricular rate in relation to time in both treatment groups

Treatment groups	Time (minutes after administration of treatment)				
	2	5	10	15	20
Diltiazem	25.6 (12)	30.7 (9.7)	33.6 (8.4)	34.5 (8)	35.9 (6.6)
Metoprolol	17.5 (11.6)	20.4 (11.8)	24.3 (11.6)	25.9 (11.5)	28.9 (10.9)
p value	p<0.05	p<0.01	p<0.01	p<0.01	p<0.05

Table 3 Treatment success ratios (%) in relation to time

Treatment groups	Time (minutes after administration of treatment)				
	2	5	10	15	20
Diltiazem	50	60	75	90	90
Metoprolol	15	35	60	65	80
p value	p<0.05	p>0.05	p>0.05	p>0.05	p>0.05

ventricular rate and the systolic and diastolic blood pressures of the two treatment groups before treatment.

None of the patients achieved sinus rhythm. A significant decrease in the ventricular rate was observed in both treatment groups after at 2 minutes ($p<0.01$). The percentage decrease in ventricular rate was significantly higher in the diltiazem group than in the metoprolol group at 2, 5, 10, 15, and 20 minutes. Diltiazem was found to have a significantly higher success rate at 2 minutes than metoprolol. The success rate in the diltiazem group appeared to be higher than metoprolol group at each time interval, however, there was no statistically significant difference between the two groups at 5, 10, 15, and 20 minutes.

At 20 minutes, a mean decline of 15.5/9.8 mm Hg and 22.3/11.5 mm Hg in the systolic/diastolic blood pressures was observed in the diltiazem and metoprolol groups, respectively. There was no significant difference between the decrease of blood pressure in the two treatment groups. None of the patients had hypotension.

DISCUSSION

Diltiazem is a calcium channel blocker classified as a class IV antiarrhythmic in the Vaughan-Williams classification. It slows the conduction through the AV node and prolongs AV nodal refractoriness when the AV nodal conduction rates are high. Hence it is commonly used in supraventricular tachycardias.¹²⁻¹⁴ In a study comparing the efficacy of diltiazem and digoxin in 30 patients with AF and atrial flutter with rapid ventricular rate, Schreck *et al* reported that the mean heart rate decreased significantly (from 150/min to

111/min) after IV diltiazem at 5 minutes and that IV diltiazem was more effective than IV digoxin for emergent control of ventricular rate.¹⁴ In an out-of-hospital study on 43 patients (38 AF, 4 atrial flutter, 1 supraventricular tachycardia), Wang *et al* reported that sinus rhythm returned in four patients, ventricular rate decreased to ≤ 100 /min in 20 patients, heart rate decreased $>20\%$ in 11 patients, and the overall success rate was 81% with IV diltiazem.¹⁶ Goldenberg *et al*, in a study of patients with AF, atrial flutter, and moderate to severe congestive heart failure, reported a high therapeutic response (83.7% with 0.25 mg/kg and 97.3% with an additional 0.35 mg/kg) with IV diltiazem in controlling rapid ventricular rate.¹⁷

In our study, successful ventricular rate control was achieved in 18/20 patients (90%) in the diltiazem group at 20 minutes. The remaining two patients required an additional dose of 0.35 mg/kg diltiazem for rate control. Half of the patients had a rapid response to diltiazem at 2 minutes. None of the patients had hypotension.

β Blockers are class II antiarrhythmic drugs whose physiological effects are a result of their competitive inhibition of catecholamine binding to β -adrenoceptor sites. They slow AV nodal conduction and prolong AV nodal refractoriness, so they are useful in supraventricular tachyarrhythmias. The effect of metoprolol, which is the only parenteral β blocker preparation available in Turkey, on ventricular rate has been proved in several studies.¹⁵⁻¹⁹ In a study on the patients with supraventricular tachyarrhythmias, Amsterdam *et al* reported that the mean heart rate decreased by more than 15% in 11 of 16 patients (69%) (9 of 11 patients with AF (82%)) with a mean dose of 9.5 mg metoprolol. Hypotension was observed in five patients.¹⁸

In our study the desired ventricular rate control was achieved in 16 of 20 patients (80%) in the metoprolol group at 20 minutes. In the remaining four patients the therapeutic effect was achieved with IV diltiazem, 0.25 mg/kg (only one of these patients needed an additional dose of diltiazem, 0.35 mg/kg). None of the patients had hypotension.

In conclusion, our study showed both diltiazem and metoprolol were effective and safe in controlling rapid ventricular rate in AF. However, the rate control effect of diltiazem began earlier and the percentage decrease in

Table 4 Mean (SD) blood pressure in both treatment groups in relation to time. Values are mm Hg

Treatment group	Time (minutes after administration of treatment)					
	0	2	5	10	15	20
Diltiazem						
SBP	136.5 (29.8)	128.7 (24.8)	124.5 (22.6)	122 (21.9)	121 (21.4)	121 (19.9)
DBP	86 (15.1)	81.7 (12.9)	78.5 (12.2)	77.5 (11.3)	76.5 (11.2)	76.2 (11.3)
Metoprolol						
SBP	143 (22.5)	134 (22.2)	129.2 (19.0)	125.5 (19.9)	124.2 (18.0)	81.5 (10.1)
DBP	93 (13.8)	88 (13.3)	85 (11.3)	84 (11.4)	82 (10.5)	120.7 (18.1)
p value	p>0.05	p>0.05	p>0.05	p>0.05	p>0.05	p>0.05

SBP, systolic blood pressure; DBP, diastolic blood pressure.

ventricular rate at different time intervals in the diltiazem group was higher in the metoprolol group.

Authors' affiliations

C Demircan, H I Cikriklar, Z Engindeniz, H Cebicci, N Atar, V Guler, E O Unlu, B Ozdemir, Uludag University Medical Faculty Hospital, Bursa, Turkey

Competing interests: none declared

REFERENCES

- 1 **Feinberg WM**, Blackshear JL, Laupacis A, *et al*. Prevalence, age distribution, and gender of patients with fibrillation. Analysis and implications. *Arch Intern Med* 1995;**155**:469–73.
- 2 **Kannel WB**, Abbott RD, Savage DD, *et al*. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. *N Engl J Med* 1982;**306**:1018–22.
- 3 **Wolf PA**, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. *Arch Intern Med* 1987;**147**:1561–4.
- 4 **Wellens HJJ**, Rodriguez LM, Smeets LRM, *et al*. Tachycardiomyopathy in patients with supraventricular tachycardia with emphasis on atrial fibrillation. In: Olsson SB, Allessie MA, Campbell RWF, eds. *Atrial Fibrillation: Mechanism and Therapeutic Strategies*. New York: Futura Publishing Company, 1994:333–42.
- 5 **Zipes DP**. Specific arrhythmias: diagnosis and treatment. In: Braunwald E, ed. *Heart Disease: A Textbook of Cardiovascular Medicine*. 5th edn. Philadelphia: WB Saunders Company, 1997:640–704.
- 6 **Pritchett ELC**. Management of atrial fibrillation. *N Engl J Med* 1992;**326**:1264–71.
- 7 **Hagens VE**, Van Gelder IC, Crijns HJ. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation. *Card Electrophysiol Rev* 2003;**7**:118–21.
- 8 **Wyse DG**, Waldo AL, DiMarco JP, *et al*. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002;**347**:1825–33.
- 9 **Shettigar UR**. Management of rapid ventricular rate in acute atrial fibrillation. *Int J Clin Pharm Ther* 1994;**32**:240–5.
- 10 **Waldo AL**, Prystowsky EN. Drug treatment of atrial fibrillation in the managed care era. *Am J Cardiol* 1998;**81**(5A):23C–29C.
- 11 **Werkö L**. Atrial fibrillation: Introduction. In: Olsson SB, Allessie MA, Campbell RWF, eds. *Atrial Fibrillation: Mechanism and Therapeutic Strategies*. New York: Futura Publishing Company, 1994:1–13.
- 12 **Phillips BG**, Gandhi AJ, Sanoski CA, *et al*. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. *Pharmacotherapy* 1997;**17**:1238–45.
- 13 **Dias VC**, Weir SJ, Ellenbogen KA. Pharmacokinetic and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. *Circulation* 1992;**86**:1421–8.
- 14 **Schreck DM**, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. *Ann Emerg Med* 1997;**29**:135–40.
- 15 **Rizos I**, Senges J, Javernig R, *et al*. Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia. *Am J Cardiol* 1984;**53**:1022–7.
- 16 **Wang HE**, O'Connor RE, Megargel RE, *et al*. The use of diltiazem for treating rapid atrial fibrillation in the out-of-hospital setting. *Ann Emerg Med* 2001;**37**:38–45.
- 17 **Goldenberg IF**, Lewis WR, Dias VC, *et al*. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. *Am J Cardiol* 1994;**74**:884–9.
- 18 **Amsterdam EA**, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. *J Clin Pharmacol* 1991;**31**:714–18.
- 19 **Hazard PB**, Burnett CR. Treatment of multifocal atrial tachycardia with metoprolol. *Crit Care Med* 1987;**15**:20–5.

bmjupdates+

bmjupdates+ is a unique and free alerting service, designed to keep you up to date with the medical literature that is truly important to your practice. bmjupdates+ will alert you to important new research and will provide you with the best new evidence concerning important advances in health care, tailored to your medical interests and time demands.

Where does the information come from?

bmjupdates+ applies an expert critical appraisal filter to over 100 top medical journals. A panel of over 2000 physicians find the few 'must read' studies for each area of clinical interest.

Sign up to receive your tailored email alerts, searching access and more...

www.bmjupdates.com

PostScript

CORRECTIONS

doi: 10.1136/emj.2004.015586corr1

In the short report titled, Not all cases of neck pain with/without torticollis are benign: unusual presentations in a paediatric accident and emergency department (*Emerg Med J* 2005; 22:645–8) two errors have occurred. The corresponding address for A Natarajan is incorrect and should be Consultant Paediatrician, anatarajan@hotmail.com. The second error is in the legend for figure 1. It should read 'T1-weighted MRI scan of the cervical spine showing a large intramedullary tumour in the cervical and upper thoracic region C1-T2.' The journal apologises for these errors.

doi: 10.1136/emj.2003.11403corr1

An author's error occurred in the paper titled Hazardous drinkers in the accident and emergency department—Who accepts advice? (*Emerg Med J* 2004;21:491–2). Incorrect proportions for 'Believed initial AED attendance related to drinking' appear in table 1 (A). The figures were calculated using a denominator based on the number of responses to that item, rather than the number of patients who were offered advice. The correct proportions are 49.9 for 'Accepted advice' and 45.9 for 'Did not accept advice' (not 70.1 and 69.8 as stated in the text). The difference in proportion (95% CI) should read 4.0 (-2.1 to 10.1).

doi: 10.1136/emj.2003.10247corr1

In the paper titled, Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation (*Emerg Med J* 2005;22:411–4) an error has occurred in table 4. At 20 minutes, places of systolic and diastolic pressures were exchanged. The author apologises for this error.

doi: 10.1136/emj.2005.002005

In part 15 of the ABC of community emergency care (*Emerg Med J* 2005;22: 564–71) the legend for figure 2 is incorrect. It should read 'Sixth nerve palsy right eye: failure of abduction. Courtesy of Dr P Marazzi/SPL model released'.

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking authors:

- Child health: nocturnal enuresis
- Eye disorders: bacterial conjunctivitis
- Male health: prostate cancer (metastatic)
- Women's health: pre-menstrual syndrome; pyelonephritis in non-pregnant women

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *Clinical Evidence* editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every six months using any new, sound evidence that becomes available. The *Clinical Evidence* in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.
- To expand the topic to include a new question about once every 12–18 months.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).